Imagining the Dalit Identity: An Analysis of Narrative Techniques in Select Dalit writing

This paper analyses the narrative techniques of two Dalit texts; an autobiography called Joothan by Omprakash Valmiki and a novel called Koogai: The Owl by Cho. Dharman. Through this analysis, the paper presents an account of the changing socio-political conditions of the Dalits in India after independence. Using the theoretical framework of narratology, the paper argues that the two very different narrative styles present in these two texts are reflective of the respective conditions within which their writers found themselves in and the larger socio-political questions that the Dalit emancipation movement was dealing with during those periods. Another aspect that the paper covers is how these two texts present the inherent conflicts and contradictions within the Dalit identity. It then asks the question whether these contradictions should be flattened to present a more homogeneous conceptualisation of what it means to be a Dalit or whether the identity should be imagined alongside these contradictions

Effekte einer akuten Dosis Ethanol auf bestimmte Aminosäuren und verwandte Verbindungen in Plasma, Aorta, Herz, Pancreas und Bronchus von Ratten

Effekte einer akuten Dosis Ethanol (2g/kg, IP) auf bestimmte Aminosäuren und verwandte Verbindungen wurden untersucht. Die Aminosäurespiegel bzw. deren Verteilung ist ähnlich, aber nicht gleich, in den verschiedenen Geweben. In den verschiedenen Geweben fanden wir teilweise erniedrigte Spiegel, teilweise aber auch erhöhte Spiegel nach Ethanol-Gabe. Diese Veränderungen bezogen sich 1. auf die einzelnen Aminosäuren oder 2. auf die unterschiedlich- en Gewebe. Eine Anzahl Korrelationen einiger Aminoverbindungen in Plasma oder Geweben wurde gefunden, waren aber oft unterschiedlich zwischen Kontroll- und Ethanolratten. Ethanol-induzierte Veränderungen in den Geweben korrelieren im Allgemeinen nicht mit den Veränderungen im Plasma und sind meistens für die untersuchten Gewebe spezifisch

An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology

BACKGROUND: In humans, serotonin has typically been investigated as a neurotransmitter. However, serotonin also functions as a hormone across animal phyla, including those lacking an organized central nervous system. This hormonal action allows serotonin to have physiological consequences in systems outside the central nervous system. Fluctuations in estrogen levels over the lifespan and during ovarian cycles cause predictable changes in serotonin systems in female mammals. DISCUSSION: We hypothesize that some of the physiological effects attributed to estrogen may be a consequence of estrogen-related changes in serotonin efficacy and receptor distribution. Here, we integrate data from endocrinology, molecular biology, neuroscience, and epidemiology to propose that serotonin may mediate the effects of estrogen. In the central nervous system, estrogen influences pain transmission, headache, dizziness, nausea, and depression, all of which are known to be a consequence of serotonergic signaling. Outside of the central nervous system, estrogen produces changes in bone density, vascular function, and immune cell self-recognition and activation that are consistent with serotonin's effects. For breast cancer risk, our hypothesis predicts heretofore unexplained observations of the opposing effects of obesity pre- and post-menopause and the increase following treatment with hormone replacement therapy using medroxyprogesterone. SUMMARY: Serotonergic mediation of estrogen has important clinical implications and warrants further evaluation

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021

Background Rheumatoid arthritis is a chronic autoimmune inflammatory disease associated with disability and premature death. Up-to-date estimates of the burden of rheumatoid arthritis are required for health-care planning, resource allocation, and prevention. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we provide updated estimates of the prevalence of rheumatoid arthritis and its associated deaths and disability-adjusted life-years (DALYs) by age, sex, year, and location, with forecasted prevalence to 2050. Methods Rheumatoid arthritis prevalence was estimated in 204 countries and territories from 1990 to 2020 using Bayesian meta-regression models and data from population-based studies and medical claims data (98 prevalence and 25 incidence studies). Mortality was estimated from vital registration data with the Cause of Death Ensemble model (CODEm). Years of life lost (YLL) were calculated with use of standard GBD lifetables, and years lived with disability (YLDs) were estimated from prevalence, a meta-analysed distribution of rheumatoid arthritis severity, and disability weights. DALYs were calculated by summing YLLs and YLDs. Smoking was the only risk factor analysed. Rheumatoid arthritis prevalence was forecast to 2050 by logistic regression with Socio-Demographic Index as a predictor, then multiplying by projected population estimates. Findings In 2020, an estimated 17·6 million (95% uncertainty interval 15·8–20·3) people had rheumatoid arthritis worldwide. The age-standardised global prevalence rate was 208·8 cases (186·8–241·1) per 100 000 population, representing a 14·1% (12·7–15·4) increase since 1990. Prevalence was higher in females (age-standardised female-to-male prevalence ratio 2·45 [2·40–2·47]). The age-standardised death rate was 0·47 (0·41–0·54) per 100 000 population (38 300 global deaths [33 500–44 000]), a 23·8% (17·5–29·3) decrease from 1990 to 2020. The 2020 DALY count was 3 060 000 (2 320 000–3 860 000), with an age-standardised DALY rate of 36·4 (27·6–45·9) per 100 000 population. YLDs accounted for 76·4% (68·3–81·0) of DALYs. Smoking risk attribution for rheumatoid arthritis DALYs was 7·1% (3·6–10·3). We forecast that 31·7 million (25·8–39·0) individuals will be living with rheumatoid arthritis worldwide by 2050. Interpretation Rheumatoid arthritis mortality has decreased globally over the past three decades. Global age-standardised prevalence rate and YLDs have increased over the same period, and the number of cases is projected to continue to increase to the year 2050. Improved access to early diagnosis and treatment of rheumatoid arthritis globally is required to reduce the future burden of the disease. Funding Bill & Melinda Gates Foundation, Institute of Bone and Joint Research, and Global Alliance for Musculoskeletal Health